Abstract Reducing cell death during the secondary injury is a major priority in the development of a cure for traumatic spinal cord injury (SCI). One of the earliest processes that follow SCI is the excitotoxicity resulting from the massive release of excitotoxicity mediators, including ATP, which induce an excessive and/or prolonged activation of their receptors and a deregulation of the calcium homeostasis. Diadenosine tetraphosphate (Ap 4 A) is an endogenous purinergic agonist, present in both extracellular and intracellular fluids, with promising cytoprotective effects in different diseases including neurodegenerative processes. In a search for efficient neuroprotective strategies for SCI, we have tested the capability of Ap 4 A to reduce the excitotoxic death mediated by the ATP-induced deregulation of calcium homeostasis and its consequences on tissue preservation and functional recovery in a mouse model of moderate contusive SCI. Our analyses with the murine neural cell line Neuro2a demonstrate that treatment with Ap 4 A reduces ATP-dependent excitotoxic death by both lowering the intracellular calcium response and decreasing the expression of specific purinergic receptors. Follow-up analyses in a mouse model of contusive SCI showed that acute administration of Ap 4 A following SCI reduces tissue damage and improves motor function recovery. These results suggest that Ap 4 A cytoprotection results from a decrease of the purinergic tone preventing the effects of a massive release of ATP after SCI, probably together with a direct induction of anti-apoptotic and pro-survival pathways via activation of P2Y 2 proposed in previous studies. In conclusion, Ap 4 A may be a good candidate for an SCI therapy, particularly to reduce excitotoxicity in combination with other modulators and/or inhibitors of the excitotoxic process that are being tested.
Introduction
Cell death is one of the features in the causes of the disabilities induced by traumatic spinal cord injuries (SCI). SCI induces an immediate first wave of neural cell death, mainly necrotic, followed by delayed oligodendrocyte and neuronal death that extends the injury in time and space along the spinal cord [1] .One of the earliest processes that follow SCI is the excitotoxicity that results from the massive release of excitatory mediators, which induce an excessive and/or prolonged activation of their receptors and the deregulation of the calcium homeostasis [2] . Excitotoxicity leads to mitochondrial dysfunction, oxidative stress, or endoplasmic reticulum stress (see in Fig. 1 ) that finally converge in the activation of both intrinsic and extrinsic pathways of apoptosis [3] [4] [5] [6] [7] .
The major mediator in the excitotoxic processes is glutamate either released by breakage of the plasma membrane of necrotic neural cells or by massive synaptic release due to unbalance of the membrane potential and increase in intracellular sodium and calcium concentration [3, 8, 9] . However, following trauma to the central nervous system, including SCI, large amounts of ATP and other nucleotides are also released by the damaged tissue [10] [11] [12] . Released ATP acts as an excitotoxin inducing the activation of the purinergic system and leading to a direct calcium-dependent excitotoxic cell death of neurons [13] [14] [15] [16] and oligodendrocytes [17] , or indirectly, favoring glutamate release from neurons [18, 19] and glia [20] .
Nucleotides and nucleosides are key signaling molecules that interact with two basic types of membrane purinergic receptors, the nucleoside P1 receptors and the nucleotide P2 receptors. The P2 receptors are additionally subclassified into ionotropic P2X receptors and metabotropic P2Y receptors [21] [22] [23] [24] . This is a primitive system with a wide range of physiological and pathologic functions that include neurotransmitter and co-transmitter activity in the central, peripheral, and autonomous nervous systems, as well as activity in pain and mechanosensory transduction [25] [26] [27] [28] . Several P2 receptors, including P2X 4 and P2X 7 , are proposed to mediate various aspects of neural cell signaling in SCI and stroke, such as the remodeling and reparation of damaged tissue, induction of gliosis, formation of the glial scar, development of inflammatory and pain processes or excitotoxic cell death [29] [30] [31] [32] [33] [34] .
Recent therapeutic approaches are trying to attenuate excitotoxic neural death after SCI. As a result, riluzole-a sodium channel blocker that decreases the pre-synaptic glutamate release by reducing the membrane potential depolarization and the derived calcium influx-has entered clinical phase II-B/III for SCI treatment [35] [36] [37] [38] [39] . In addition, minocycline, an antibiotic, anti-apoptotic, and anti-inflammatory drug [40, 41] , that also has anti-excitotoxic effects [42] is already in clinical Fig. 1 Excitotoxic-induced cell death pathways. Massive release of glutamate and ATP from necrotic and broken cells at trauma level activates NMDA and purinergic receptors expressed in neighbor cells. The subsequent increase in intracellular calcium concentration induces the activation of several cell death pathways implying endoplasmic reticulum and oxidative stress, autophagy, pro-apoptotic caspase cleavage, etc. All these mechanisms are part of the secondary wave of neural death activated minutes to few days after injury in the spinal cord phase III for SCI treatment [43] . Following these approaches, we hypothesize that modulation of the purinergic system may be beneficial against the excitotoxic damage induced by the massive release of ATP after SCI. Previous evidences suggest a beneficial role of blocking purinergic receptors in similar neuropathological conditions. Blockade of P2X 7 with PPADS, oxo-ATP [10] , or brilliant blue G [44] provides neuroprotection in rat models of traumatic SCI resulting in the reduction of neuronal damage, microglial activation, neutrophil infiltration, and inflammatory response and increasing tissue preservation, although other groups failed to reproduce brilliant blue G results [45] .
Among the purines, diadenosine polyphosphates (Ap n As) emerge as interesting therapeutical molecules. They are partial agonists, and even antagonists in presence of the full agonist, of different P2 receptors [46] [47] [48] [49] [50] that may induce a decrease in the receptor response and a negative modulation of the calcium response. They comprise a group of compounds formed by the union of two adenosine moieties linked by their ribose 5′-ends by a 2 to 7 phosphate chain. Ap n As act on both P2X (1, 2, 3, and 4) [48, 51, 52] and P2Y (1, 2, 4, 12, and 13) [52] [53] [54] [55] [56] [57] purinergic receptors and diadenosine-specific receptors or P4 receptors [58] . They are naturally present in the cytoplasm of eukaryotic and prokaryotic cells [59] , co-stored with ATP in granules of platelets and chromaffin cells and in synaptic vesicles of the cholinergic synaptic terminals [60] [61] [62] [63] , and present in several types of fluids. Ap n As regulate the function and composition of tears [64] , intraocular pressure [65] , and increase wound healing capacities of the cornea [66] . Among Ap n As, the diadenosine with a 4-phosphate bridge or P1-P4-di (adenosine-5′), tetraphosphate (Ap 4 A) is neuroprotective against ocular sympathetic nerve degeneration induced by 6-hydroxidopamine (6-OHDA) [67] and protects brain against ischemia,6-OHDA [68] or methamphetamine [69] exposure. Though this general neuroprotective effect is known, its role in SCI has not been explored yet. In the present work, we have used in vitro analyses in neural cell lines to determine the ability of Ap 4 A to reduce neuronal cell death by reducing the excitotoxic rise in intracellular calcium concentration and in vivo studies in a mouse model of contusive spinal cord injury to evaluate its therapeutic potential to reduce tissue damage and to ameliorate locomotor impairment following SCI.
Material and methods

In vitro experiments
Cell culture at 37°C. After 5 to 10 min reading, 5 μl of control (Krebs' buffer) or a 10-fold concentrated ATP solution (final concentration of 300 μM) was added to each well by means of the injector system, and the fluorescence was measured for an additional 10 to 50 min. The ratio (R) of light excited at 340 nm to that at 380 nm was converted into Ca 2+ concentration using the method of Grynkiewiczet al. [70] . An in situ Kd value for fura-2 of 350 nM was used [71] . Rmin was obtained by bathing cells in a Ca 
Western blot
After treatment, cells were mechanically detached from the plate and lysed in buffer containing 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; Merck, Darmstadt, Germany), 150 mM sodium chloride (NaCl; Sigma-Aldrich), 1 % nonyl phenoxypolyethoxylethanol (Tergitol type NP40; Sigma-Aldrich), 1 % sodium deoxycholate (DOC; Sigma-Aldrich), 10 % glycerol (USB Corporation, Affymetrix, Santa Clara, CA, USA), 10 mM magnesium chloride (MgCl 2 ; Sigma-Aldrich), 2 mM 3-[(3-cholamidopropyl)-dimethylammonium]-1-propane sulfonate (CHAPS; Sigma-Aldrich), 0.1 % sodium dodecyl sulfate (SDS; Sigma-Aldrich), 2 mM ethylenediaminetetraacetic acid (EDTA, USB Corpotation), and 1 tablet of Complete protease inhibitor cocktail (Roche, Basel, Switzerland) every 50 ml of buffer. Samples were sonicated and cleared by centrifugation (10,000×g for 15 min at 4°C). The protein content was determined by the Bradford method.
Homogenates containing 50-100 mg of protein were separated using conventional SDS-polyacrylamide gel electrophoresis in reducing conditions (5 % β-mercaptoethanol; Sigma-Aldrich) and transferred to 0.45 μm pore size polyvinylidenedifluoride membrane (PVDF, Immobilon, Merck Millipore; Darmstadt, Germany). The membrane was blocked with a solution of 5 % nonfat milk in TBS-T (Tris buffer saline plus 0.05 % (v/v) Tween20) for 1 h at room temperature (RT) and then incubated with the following primary antibodies diluted in blocking solution: anti-P2X 1 (1:500; Alomone Labs (Jerusalem, Israel) cat#APR-001, RRID:AB_2040052), anti-P2X 2 (1:500; Alomone Labs cat#APR-003, RRID:AB_2040054), anti-P2X 4 (1:500; Alomone Labs cat#APR-002, RRID:AB_2040058), anti-P 2 X 7 ( 1 : 5 0 0 ; A l o m o n e L a b s c a t # A P R -0 0 8 , RRID:AB_2040065), anti-P2Y 1 (1:500; Alomone Labs cat#APR-009, RRID:AB_2040070), anti-P2Y 2 (1:500; Alomone Labs cat#APR-010, RRID:AB_2040078), anti-P 2 Y 6 ( 1 : 5 0 0 ; A l o m o n e L a b s c a t # A P R -0 1 1 , RRID:AB_2040082), and β-tubulin (1:1000; Sigma-Aldrich Cat# T5293, RRID:AB_477580) as loading control. Primary antibodies were incubated overnight at 4°C followed by incubation at RT for 1 h with the corresponding secondary antibody diluted in 5 % non-fat milk in TBS-T buffer: HRPconjugated goat anti-rabbit (1:10.000; ThermoFisher Scientific cat#31,460; RRID:AB_228341) or HRPconjugated goat anti-Mouse (1:10.000; ThermoFisher Scientific cat#31,430; RRID:AB_228307) and developed using the enhanced chemiluminescence detection system (ECL; Pierce, ThermoFisher Scientific). All employed antibodies recognized the specific band or bands of the expected molecular weight.
In vivo experiments
C57BL/6J mice (Harlan Laboratories, Indianapolis, IN, USA) were housed in plastic cages in a temperature and humidity controlled room maintained on a 12:12 h reverse light/dark cycle with free access to food and water. Animal experimental procedures were in accordance with the European Communities Council Directive (2010/63/EU) and were approved by the Hospital Nacional de Parapléjicos Animal Care and Use Committee (ref# 63/2010).
SCI procedure, treatment, and locomotor recovery assays
Female mice 20 g of weight (12-14 weeks of age) were anesthetized through isoflurane (Forane, Baxter Health Care Corporation, Deerfield, IL, USA) inhalation (2 % in oxygen for induction and 1.5 % during surgery). The spinal cord was exposed by laminectomy in the 9th thoracic vertebrae (T9) and subsequently received a 50 Kdyne contusion using an IH Spinal Cord Impactor device (Precision System & Instrumentation, Lexington, KY, USA). After surgery, animals were maintained by daily manual bladder emptying for 2 weeks and by administration of Buprenorfine as analgesic (0.03 mg/Kg Buprex; Reckitt Benckiser Pharmaceuticals Limited, Richmond, VA, USA) and enrofloxazine as antibiotic (0.4 mg/Kg Baytril; Bayer AG, Leverkusen, Germany) for 2 days. The Sham group of animals was laminectomized but not contusioned.
As excitotoxic process starts minutes after injury, a first dose of Ap 4 A was administered directly on the contused area of the spinal cord by placing a 1-mm 2 
Motor function recovery
The rate of motor function recovery was assessed in an open field weekly for 3 to 7 weeks after injury following the Basso Mouse Scale (BMS) [74] . Evaluations of each individual were performed for 4 min by two observers blinded to the treatment. The correspondent subscore scales were also used analyzing the different parameters individually for a more extensive analysis of certain motor features.
Motor function was also evaluated according to the rotarod performance test [75] . Weekly, animals were placed in a mouse rotarod 47600 device (UgoBasile, Gemonio, Varese, Italy) with accelerated rotational movement (from 4 to 40 rpm in 5 min test). The latency time it takes the mouse to fall off the rod was measured in three trials separated by 15 min rest.
Histology
Twenty-one days after surgery, animals were euthanized with a lethal dosage of sodium pentobarbital and transcardially perfused with saline buffer with sodium heparin (1 unit/ml; ChiesiEspaña, Barcelona, Spain) followed by 50 ml of 4 % (w/v) paraformaldehyde in 0.1 M phosphate buffer pH 7.4. A segment of 1 cm of spinal cord around the injured area was removed, post-fixed in 4 % paraformaldehyde solution (overnight at 4°C), and cryoprotected in 30 % (w/v) sucrose (1-2 days at 4°C). Finally, tissue was embedded in optimum cutting temperature compound (OCT; Tissue-Tek, Sakura Finetek Europe B.V. Alphen aan den Rijn, the Netherlands) and frozen (−20°C). Embedded tissue was cut in 20 μm sections using a cryostat (HM560, Microm GmbH, Walldorf, Germany) and mounted in microscope glass slides (Superfrost Plus, ThermoFisher Scientific, Waltham, MA, USA).
Eriochrome cyanine stain of myelin
To determine the area and volume of spared tissue, we followed a modified method of Eriochrome Cyanine staining from Rabchevsky and colleagues [76] . Briefly, spinal cord sections were sequentially stained with Eriochrome Cyanine followed by counter-staining with 5 % iron Alum and BoraxFerricyanide solutions. After dehydration with increasing concentrations of ethanol and Histochoice Cleaning Agent (Sigma-Aldrich), the samples were mounted using DPX Mountant (Sigma-Aldrich). This protocol stained white matter myelin and allowed us to differentiate the spared white matter from the grey matter or the damaged tissue. The area and volume of spared white matter were estimated through the stereological analysis of sections comprising 1 cm around the epicenter (100 μm between sections), using the Cavalliery method in a Stereology Microscope (Olympus BX61, Center Valley, PA, USA).
Data analysis
All data are expressed as mean ± SEM unless specifically stated. Statistical significance of the treatment effects was tested using unpaired Student's t test, one-way ANOVA with Tukey post hoc test, or chi-square test depending to the characteristics of the data. The correlation between locomotor improvements and tissue conservation was calculated using the Pearson's Correlation Coefficient. All analyses were conducted in Prism Software 5 (GraphPad Software Inc., La Jolla, Ca, USA). Differences were considered statistically significant when P < 0.05. To explore the processes involved in Ap 4 A cytoprotection, we evaluated the effects Ap 4 A on ATP-induced calcium rise in Neuro-2a cells loaded with the ratiometric calcium sensitive dye fura-2. The addition of ATP (300 μM) increased intracellular calcium from a baseline of 96.39 ± 6.11 nM to a fast peak of 538.46 ± 110.94 nM (a 4.58-fold increase; n = 9; Fig. 3a, b) due to P2X receptor activation and a posterior slow rate increase due to P2Y receptor activation. Pre-incubation with Ap4A (100 μM) for 24 h did not change the intracellular calcium baseline concentration (99.92 ± 10.84 nM) but significantly reduced both the fast peak (290.85 ± 25.88 nM; a 1.91-fold increase; T15 = 2.32; p = 0.017 vs. ATP alone, n = 9) and the slow increase induced by ATP. (Fig. 4a-c) . Higher Ap 4 A concentrations (300 and 1000 μM) did not elicit any further increase in intracellular calcium concentrations (data not shown). However, in agreement with the degradation of purinergic receptors associated showing an increase in cell death due to ATP treatment that was significantly reduced by Ap 4 A pre-treatment (mean ± standard deviation, n = 3). ***p < 0.001; **p < 0.01; *p < 0.05; n.s = non significant (Student's t test) (Fig. 4d, e) . Therefore, Ap 4 A seems to reduce ATP-induced cell death and calcium entrance through both proposed mechanisms, partial agonism and receptor repression.
Results
Ap
Ap 4 A treatment improves motor function recovery after SCI in mice
To explore the therapeutic potential of Ap 4 A, we evaluated the locomotor recovery in injured mice treated with Ap 4 A or vehicle. According to the Basso Mouse Scale (BMS), before injury, all mice reached the maximum score of 9 points in the scale. SCI caused a total loss of hind limb locomotor ability during the first 2 days post-injury (DPI), with a BMS score of 0 or 1 (Fig. 5a) . Locomotion was partially recovered spontaneously at 21 DPI in vehicle-treated animals, reaching a final BMS score of 5.14 ± 0.23 (n = 7). Intraperitoneal injection of 20 mg/Kg Ap 4 A per day during 7 days induced a faster and larger locomotor recovery, up to 6.83 ± 0.41 points in the BMS score at 21 DPI (n = 9). A lower dose (10 mg/Kg) led to much lesser improvements in motor function recovery (data not shown). Comparison of the BMS subscores emphasize the differences between the vehicle-treated animals (2.56 ± 0.63 at 21 DPI; n = 7) and the 20 mg/Kg Ap 4 A-treated group (7.55 ± 0.80; n = 9) (Fig. 5b ). Differences were particularly large when considering the capacity of injured mice to perform coordinative walk between forelimbs and hindlimbs. An individualized analysis revealed that a significantly higher number of Ap 4 A-treated mice recovered a mostly coordinated locomotion than vehicle-treated mice (86 vs. 20 % at 21 DPI, respectively; Fisher exact test p = 0.046) (Fig. 5c) .
Coordinative skills together with balance capacities were also evaluated using the rotarod performance test [75] , which determines the time that mice remain in an accelerating rod before falling (latency time) (Fig. 5d) . In these setting, sham animals were able to remain in the device 173.60 ± 18.35 s (n = 9), whereas vehicle-treated group significantly worsen their performance, remaining 77.28 ± 14.83 (n = 5) and 70.5 ± 6.93 s (n = 6) at 14 and 21 DPI, respectively (T 12 (Fig. 6a, b) . Ap 4 A treatment significantly increased white matter preservation in sections caudal to the injury site (45.41 ± 1.60 % white matter volume from 0.2 to 0.6 mm vs. 33.66 ± 1.96 % in vehicle-treated group; T 9 = 4.06, P = 0.0014, n = 4-7; Fig. 6c) . Moreover, while the relative area of white matter in Ap 4 A-treated mice reached extensions similar to sham individuals (around 50 %) in sections separated 0.4-0.5 mm caudal to the epicenter, vehicle-treated animals did not reached a similar preservation until 0.6-0.7 mm away from the epicenter (Fig. 6b) . Conversely, vehicle and Ap 4 Atreated groups did not show differences in tissue preservation at the epicenter or the adjacent rostral sections.
Accordingly, motor function recovery at 21 DPI (BMS score) was significantly correlated with tissue preservation in sections caudal to the injury (Pearson's correlation coefficient = 0.6507, p = 0.03) but not with preservation at the epicenter or in sections rostral to the injury (Pearson's correlation coefficients −0.0627 and 0.0612 respectively, n = 4-7 mice; Fig. 6d ).
Discussion
Neuroprotection is a major priority in the development of an effective therapy for traumatic spinal cord injury [77] . Several approaches are being tested [78, 79] , but only high-dose intravenous administration of methylprednisolone has reached the clinical practice with controversial benefits [80] . In search for efficient neuroprotective strategies, we have evaluated the ability of diadenosine tetraphosphate (Ap 4 A) to reduce the excitotoxic death mediated by the ATP-induced deregulation of calcium homeostasis and its consequences on tissue preservation and functional recovery in a mouse model of moderate contusive SCI.
Our studies with the mice-derived neural cell line Neuro2a indicate that Ap 4 A treatment protects neural cells from death induced by administration of excitotoxic concentrations of ATP, as reported in other cellular models of neuronal death induced by methamphetamine [69] , ischemia or 6-hydroxydopamine [68] . Neuroprotection was highest when cultures were pre-incubated with Ap 4 A for 24 h before ATP stimulation. Pre-treatment with Ap 4 A reduced the rise of intracellular levels of calcium induced by ATP. As shown in Fig. 4d and in the literature, Neuro2a cells express several types of P2X ligand-gated ion channel receptors [81] and Gprotein-coupled P2Y receptors [82] . Both the fast peak, under control of P2X receptors, and the slow rate increase, under control of P2Y receptors, were reduced by Ap 4 A. This result agreed with a reduction in the levels of Ap 4 A purinergic receptors P2X 2 , P2Y 1 , and P2Y 2 , suggesting that regulation of calcium levels may result from a ligand-induced internalization and degradation of ATP purinergic receptors, a wellknown regulatory mechanism of the function of several P2X [83] [84] [85] [86] [87] [88] and P2Y receptors [89, 90] . However, Ap 4 A failed to reduce the expression of P2X 1 , P2X 4 , both ionotropic receptors for which Ap 4 A is a partial agonist. Interestingly, Ap 4 A treatment also reduced the expression of P2X 7 , which is not receptor for Ap 4 A [91] , suggesting that Ap 4 A can activate alternative regulatory mechanisms for non-target purinergic receptor internalization and degradation. Further studies are required to clarify the different response of these receptors. Ap 4 A can also negatively modulate the calcium response to ATP and the consequent excitotoxic cell death by competing for receptors shared by both purines [92] [93] [94] . As we mentioned before, Ap 4 A is partial agonist for P2X 1 and P2X 4 , full agonist but less potent than ATP for P2X 2 and P2X 3 [48] and partial agonist on P2Y 1 , P2Y 2 , and P2Y 12 , antagonizing the effects of ATP [49, 50] . According to our experiments, Ap 4 A increases intracellular calcium, without reaching the cytotoxic levels elicited by ATP, and when co-administered with ATP, Ap 4 A protects Neuro2a cells from ATP excitotoxicity, although to a much lesser extent than when Ap 4 A is administered 24 h before (see Fig. 2 ).
Together, these results demonstrate the cytoprotective effects of Ap 4 A on ATP-induced excitotoxicity, due to the internalization and degradation of P2X receptors reducing the entrance of extracellular calcium and likely of P2Y receptors decreasing the long-term mobilization of calcium from intracellular reservoirs. However, we cannot exclude other effects on pathways associated to the activation of the P2Y and P2X receptors. However, we cannot exclude other effects on pathways associated to the activation of the P2Y and P2X receptors. The mobilization of calcium can be also due to the activation of voltage-dependent calcium channels by different types of diadenosine polyphosphates [58, 95] , which expression or function could be affected by the 24 h pre-incubation with Ap 4 A. In addition, Ap4A has been described as alarmone-low molecular weight intracellular compounds that are synthesized in response to a specific metabolic stress and that act homeostatically to increase the probability of cell survival-regulating cellular metabolic state and/or gene expression [96] . Ap 4 A cytoprotection can be also a consequence of the effects of its hydrolysis to adenosine, as previously described [97] , although preliminary data from an ongoing study using adenosine deaminase to transform adenosine in inosine indicates that adenosine does not participate in Ap 4 A cytoprotection.
The cytoprotective effects of Ap 4 A in vitro demonstrated in the present work, together with results from previous studies in different neurodegenerative diseases [67] [68] [69] , suggested that Ap 4 A administration can be a valid neuroprotective treatment for nervous system injuries involving excitotoxic processes induced by massive ATP release, including SCI [10] [11] [12] . In agreement, we observed that intraperitoneal administration of Ap 4 A after contusion in a mouse model of SCI induces improved inter-limb coordination earlier and to a larger extent than vehicle-treated mice. Coordination is a major milestone rarely reached by untreated C57BL/6J after a moderate SCI [74, 98] that precedes a more extensive recovery [99] , depending on the conservation of local networks or propriospinal interneurons (PNs) that build up the central patterns generators (CPGs) and rhythmic locomotive movements [100, 101] . The conservation of these circuits is reflected in the increase of spared white matter in Ap 4 A-treated mice, especially in sections caudal to the injury place.
The beneficial effects of Ap 4 A treatment on a mouse model of contusive SCI have important implications. On the one hand, they confirm the contribution of ATP activation of the purinergic signaling in the development of SCI impairments, as previously shown in studies of Dr. Nedergaard's laboratory [10, 44] . According to Wang and colleagues [10] , ATP release is strongly increased in peritraumatic areas during the first 6 h following the trauma, activating purinergic receptors in some cases overexpressed after SCI (vg. P2X 4 and P2X 7 [102, 103] ). Signaling through purinergic receptors increases the concentration of intracellular calcium and induces excitotoxic death of neurons and oligodendrocytes [10] , as well as modulates the acute and chronic inflammation and neuropathic pain [104, 105] . The ATP-mediated rise of intracellular calcium also contributes to exacerbate excitotoxicity indirectly, inducing the release of glutamate [106, 107] . On the other hand, the beneficial effect of Ap 4 A treatment supports the modulation of the purinergic system as a promising neuroprotective target for SCI, as proposed by previous authors [10, 44] . However, unlike previous analyses that searched for antagonists to P2X 7 as their approach for these therapies [10] , our results indicate that other purinergic receptors, particularly the ionotropic P2Y receptors, may also be targeted to modulate ATP-induced cell death and improve functional recovery. Moreover, according to our in vitro analyses, the use of an agonist such as Ap 4 A may elicit a broader cytoprotective response based on (i) a long-term regulation of intracellular calcium concentration, (ii) internalization of purinergic receptors including P2X 7 which is overexpressed after SCI [103] , and (iii) possibly through anti-apoptotic mechanisms not explored here such as the reduction of caspase cleavage, DNA fragmentation, and activation of the Erk1/2 pro-survival pathway induced by the activation of P2Y 2 receptor [108] , one of the purinergic receptors with highest affinity for Ap 4 A [51, 109] .
Therefore, we suggest that the acute administration of an endogenous purine-signaling molecule as Ap 4 A can be a promising therapy to reduce ATP-induced excitotoxicity and other cell death pathways triggered by SCI, as already proved in the amelioration of multiple types of disease models and neurodegenerative processes [51, 67, 68] . In the present study, we have combined the systemic delivery of Ap 4 A with its topic administration taking advantage of the spinal cord exposure during the surgical procedures in order to maximize the chances of the drug to reach the damaged tissue. As a consequence, uncertainties may be risen on the contribution of each administration strategy to the observed improvements. Previous studies have already demonstrated the therapeutic potential of both topic and systemic administration of Ap 4 A in different CNS pathologies [67, 68, 110] , but information on the effects of their combination is still lacking. Therefore, additional studies will be necessary to optimize the dosage and to establish the therapeutic efficiency of each delivery system, as well as to determine the precise-direct and indirect-mechanisms underlying functional recovery, tissue sparing, and neuroprotection.
We also suggest that Ap 4 A acts in a biphasic way, with a early fast phase, which reduces calcium excitotoxicity by competing with ATP for purinergic receptors and probably reduces apoptosis by signaling through the P2Y 2 receptor to activate Erk1/2 pathway [108] , and a secondary phase in which Ap 4 A reduces the purinergic tone and calcium response promoting the internalization of purinergic receptors. Other studies have already targeted the purinergic system after SCI using P2X 7 antagonists reaching promising cytoprotective effects [10, 44] . However, contrary to the drugs employed in these approaches, Ap 4 A is an endogenous purine that does not fully antagonize ATP but functions as a partial agonist restricting intracellular calcium concentrations to non-toxic levels while activating different prosurvival pathways. Finally, we suggest that combination of Ap 4 A administration with therapies based on P2X 7 antagonists [10, 44] as well as inhibitors of glutamate derived excitotoxicity such as Riluzole [35, 39] , may lead to more efficient cytoprotective therapies for excitotoxic death in SCI.
